Emerging therapies in primary sclerosing cholangitis: pathophysiological basis and clinical opportunities
Year: 2020
Type: review
Abstract: Primary sclerosing cholangitis (PSC) is a progressive liver disease, histologically characterized by inflammation and fibrosis of the bile ducts, and clinically leading to multi-focal biliary strictures and with time cirrhosis and liver failure. Patients bear a significant risk of cholangiocarcinoma and colorectal cancer, and frequently have concomitant inflammatory bowel disease and autoimmune disease manifestations. To date, no medical therapy has proven significant impact on clinical outcomes and most patients ultimately need liver transplantation. Several treatment strategies have failed in the past and whilst prescription of ursodeoxycholic acid (UDCA) prevails, controversy regarding benefits remains. Lack of statistical power, slow and variable disease progression, lack of surrogate biomarkers for disease severity and other challenges in trial design serve as critical obstacles in the development of effective therapy. Advances in our understanding of PSC pathogenesis and biliary physiology over recent years has however led to a surge of clinical trials targeting various mechanistic compartments and currently raising hopes for imminent changes in patient management. Here, in light of pathophysiology, we outline and critically evaluate emerging treatment strategies in PSC, as tested in recent or ongoing phase II and III trials, stratified per a triad of targets of nuclear and membrane receptors regulating bile acid metabolism, immune modulators, and effects on the gut microbiome. Furthermore, we revisit the UDCA trials of the past and critically discuss relevant aspects of clinical trial design, including how the choice of endpoints, alkaline phosphatase in particular, may affect the future path to novel, effective PSC therapeutics.
Source: Journal of Gastroenterology
Authors: Mette Vesterhus, Tom Hemming Karlsen
Language: English
Topic: Liver Diseases and Immunity
Subfield: Hepatology
Field: Medicine
Domain: Health Sciences
Keywords: primary sclerosing cholangitis, new drugs, bile acid metabolism, nuclear receptors, cell surface receptors, immunomodulators, gut microbiota, ursodeoxycholic acid, clinical trial design, alkaline phosphatase, biliary strictures, cholangiocarcinoma, inflammatory bowel disease, liver transplantation
Open Access status: hybrid
Estimated APC paid: $4,480
Funder: Universitetet i Oslo
OpenAlex ID: W3013748166
